BiotechTube
GlycoMinds

GlycoMinds

San Diego, United States· Est.
glycominds.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

GlycoMinds is a private, commercial-stage diagnostics company headquartered in San Diego, California, focused on gastroenterology. Its core technology is a validated serum biomarker platform that powers the IBDX® test, used for diagnosing IBD subtypes (Crohn's Disease vs. Ulcerative Colitis), prognosticating disease course, and monitoring therapy response. The company targets a significant unmet need for non-invasive tools in the growing IBD market, positioning itself as a specialist with a clinically validated product. Its business model involves selling diagnostic reagents in the USA and kits internationally.

GastroenterologyInflammatory Bowel Disease

Technology Platform

Proprietary serum biomarker platform based on microbiome-derived glycans or immunogenic molecules for non-invasive diagnosis, prognosis, and therapy monitoring of gastrointestinal diseases.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The rising global prevalence of IBD creates a growing need for non-invasive, cost-effective diagnostic and monitoring tools.
GlycoMinds can expand by deepening the clinical utility claims of IBDX® for therapy monitoring, pursuing regulatory approvals for new indications, and leveraging its platform to develop tests for other GI conditions like Celiac Disease.

Risk Factors

Key risks include competition from other diagnostic companies and novel testing modalities, potential challenges in broad physician adoption and insurance reimbursement, and the inherent risk of a small, private company with a concentrated product portfolio facing scalability and commercial execution hurdles.

Competitive Landscape

GlycoMinds competes in the niche serological IBD testing market against larger diagnostic firms (e.g., Nestlé Health Science/Prometheus) and emerging companies developing multi-analyte tests. Its competitive edge is its long-term specialization and the specific validation of its IBDX® panel for prognosis and therapy monitoring, not just diagnosis.

More companies in Diagnostics & Precision Medicine →More companies in United States →